Literature DB >> 29230141

Current Status of Sorafenib Use for Treatment of Hepatocellular Carcinoma.

Hashem B El-Serag1, M Margaret1, Albert B Alkek1.   

Abstract

Entities:  

Year:  2017        PMID： 29230141      PMCID： PMC5718181     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  8 in total

1.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2012-04       Impact factor: 25.083

2.  Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.

Authors:  Neehar D Parikh; Vincent D Marshall; Amit G Singal; Hari Nathan; Anna S Lok; Rajesh Balkrishnan; Vahakn Shahinian
Journal:  Hepatology       Date:  2016-11-25       Impact factor: 17.425

3.  Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.

Authors:  Jorge A Marrero; Masatoshi Kudo; Alan P Venook; Sheng-Long Ye; Jean-Pierre Bronowicki; Xiao-Ping Chen; Lucy Dagher; Junji Furuse; Jean-Francois H Geschwind; Laura Ladrón de Guevara; Christos Papandreou; Tadatoshi Takayama; Arun J Sanyal; Seung Kew Yoon; Keiko Nakajima; Robert Lehr; Stephanie Heldner; Riccardo Lencioni
Journal:  J Hepatol       Date:  2016-07-25       Impact factor: 25.083

4.  TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.

Authors:  Jean-François Geschwind; Masatoshi Kudo; Jorge A Marrero; Alan P Venook; Xiao-Ping Chen; Jean-Pierre Bronowicki; Lucy Dagher; Junji Furuse; Laura Ladrón de Guevara; Christos Papandreou; Arun J Sanyal; Tadatoshi Takayama; Sheng-Long Ye; Seung Kew Yoon; Keiko Nakajima; Robert Lehr; Stephanie Heldner; Riccardo Lencioni
Journal:  Radiology       Date:  2016-01-08       Impact factor: 11.105

5.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

Review 6.  Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis.

Authors:  Richard S Finn; Andrew X Zhu; Wigdan Farah; Jehad Almasri; Feras Zaiem; Larry J Prokop; Mohammad Hassan Murad; Khaled Mohammed
Journal:  Hepatology       Date:  2018-01       Impact factor: 17.425

7.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

8.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425
  8 in total
  3 in total

1.  Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma.

Authors:  Sumit Siddharth; Panjamurthy Kuppusamy; Qitong Wu; Arumugam Nagalingam; Neeraj K Saxena; Dipali Sharma
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

2.  Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study.

Authors:  Xue-Fen Lei; Yang Ke; Tian-Hao Bao; Hao-Ran Tang; Xue-Song Wu; Zhi-Tian Shi; Jie Lin; Zhi-Xian Zhang; Hou Gu; Lin Wang
Journal:  World J Clin Cases       Date:  2018-05-16       Impact factor: 1.337

3.  Impact of tenofovir antiviral treatment on survival of chronic hepatitis B related hepatocellular carcinoma after hepatectomy in Chinese individuals from Qingdao municipality.

Authors:  Zhong Ge; Jian Ma; Bing Qiao; Yanling Wang; Haifeng Zhang; Wei Gou
Journal:  Medicine (Baltimore)       Date:  2020-08-07       Impact factor: 1.817
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.